JW 0202
Alternative Names: JW-0202Latest Information Update: 03 May 2024
At a glance
- Originator JW Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 17 Apr 2024 JW Pharmaceutical completes a phase I pharmacokinetic trial(In volunteers) in South Korea (PO) (NCT06361277)
- 03 Nov 2023 Phase-I clinical trials in Unspecified (In volunteers) in South Korea (PO) (NCT06361277)